150.49

3.28% 4.785

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $150.49, with a volume of 246.44K. It is up +3.28% in the last 24 hours and down -0.93% over the past month. Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Previous Close:

$145.70

Open:

$146.36

24h Volume:

246.44K

Relative Volume:

0.68

Market Cap:

$4.36B

Revenue:

$290.51M

Net Income/Loss:

$89.16M

P/E Ratio:

50.33

EPS:

2.99

Net Cash Flow:

$119.18M

1W Performance:

+0.14%

1M Performance:

-0.93%

6M Performance:

-19.90%

1Y Performance:

-23.81%

1-Day Range:

$145.63

$152.04

1-Week Range:

$142.51

$152.04

52-Week Range:

$122.80

$207.84

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

275

Twitter

@KrystalBiotech

Next Earnings Date

2024-11-04

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	150.49	4.23B	290.51M	89.16M	119.18M	2.99
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Aug 20, 2025

Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN

Aug 20, 2025

Aug 19, 2025

RSI + MACD Show Convergence for Krystal Biotech Inc.July 2025 Selloffs & Daily Chart Pattern Signals - newsyoung.net

Aug 19, 2025

Aug 18, 2025

AI Trend Models Suggest Bounce for Krystal Biotech Inc.July 2025 Opening Moves & High Accuracy Investment Entry Signals - newsimpact.co.kr

Aug 18, 2025

Aug 17, 2025

Can Krystal Biotech Inc. keep up with sector leadersTrade Analysis Summary & Consistent Return Investment Signals - mustnews.co.kr

Aug 17, 2025

Aug 16, 2025

Local biotech co-founder named to Forbes 50 Over 50 - MSN

Aug 16, 2025

What are Krystal Biotech Inc.’s growth leversSwing Trade & Low Risk Investment Opportunities - thegnnews.com

Aug 16, 2025

Aug 15, 2025

Krystal Biotech Inc. Matches Institutional Buying FilterWatch List & Stock Timing and Entry Methods - newsimpact.co.kr

Aug 15, 2025

Why Krystal Biotech Inc. stock attracts strong analyst attentionMarket Movers & Technical Buy Zone Confirmations - sundaytimes.kr

Aug 15, 2025

Aug 14, 2025

Support Zone Holds Steady for Krystal Biotech Inc. After Dip2025 EndofYear Setup & Real-Time Buy Signal Notifications - beatles.ru

Aug 14, 2025

Aug 13, 2025

Evercore ISI Maintains Buy Rating on Krystal Biotech with $200 Target - AInvest

Aug 13, 2025

Aug 12, 2025

Evercore Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛

Aug 12, 2025

Aug 11, 2025

Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN

Aug 07, 2025

Aug 06, 2025

Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com

Aug 06, 2025

Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest

Aug 06, 2025

Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest

Aug 06, 2025

Aug 05, 2025

Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN

Aug 05, 2025

Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest

Aug 05, 2025

Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest

Aug 05, 2025

Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance

Aug 05, 2025

A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛

Aug 05, 2025

KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Nasdaq

Aug 05, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Aug 05, 2025

Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com

Aug 05, 2025